AtriCure, Inc. ATRC R2K
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 17.4% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -63.0% CAGR over 5 years.
- Trading 34.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATRC AtriCure, Inc. R2K | 27.67 | - | $1.40B | - | -0.75% | -0.97% | 17.40% | -63.01% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 42.15M | - | 46.99M | 51.80M | 49.94M | 52.89M | 53.97M | 58.91M | 56.61M | 61.32M | 53.23M | 40.82M | 54.76M | 57.73M | 59.27M | 71.38M | 70.46M | 73.22M | 74.58M | 84.53M | 83.25M | 93.49M | 100.92M | 98.29M | 108.85M | 116.27M | 115.91M | - | 123.62M | 136.14M | 134.27M | 140.50M | 141.25M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.99M | 34.66M | 32.94M | 35.16M | 31.94M |
| Gross Profit | 25.55M | 25.91M | 28.82M | 27.47M | 28.90M | 30.01M | 32.55M | 30.92M | 32.68M | 34.50M | 38.08M | 35.95M | 38.59M | 39.87M | 43.89M | 41.80M | 44.77M | 38.88M | 27.65M | 40.33M | 42.44M | 44.54M | 54.08M | 52.23M | - | 55.59M | 63.52M | 61.71M | 69.61M | 77.08M | 73.87M | 81.27M | 86.84M | 86.79M | - | 92.63M | 101.48M | 101.33M | 105.34M | 109.31M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.58M | 107.67M | 101.12M | 102.85M | 108.78M |
| Operating Income | -10.63M | -9.42M | -7.74M | -6.29M | -7.70M | -9.64M | -6.36M | -6.85M | -2.13M | -9.43M | 958.00K | -6.05M | -2.61M | -5.32M | -3.84M | -8.64M | -15.33M | -15.45M | -7.29M | -3.99M | -17.50M | -15.88M | -15.08M | 98.67M | - | -14.15M | -13.66M | -10.72M | -5.78M | -4.14M | -8.09M | -10.92M | -7.17M | -7.41M | - | -5.95M | -6.19M | 208.00K | 2.49M | 526.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.00K | 732.00K | 6.55M | 8.97M | 7.01M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.42M | 1.49M | 1.47M | 1.50M | 1.34M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.51M | -5.93M | -86.00K | 2.36M | 394.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 239.00K | 261.00K | 181.00K | 604.00K | 286.00K |
| Net Income | -10.91M | -9.72M | -8.21M | -6.78M | -8.62M | -10.18M | -6.88M | -7.25M | -2.58M | -10.13M | -338.00K | -7.24M | -3.43M | -5.63M | -4.10M | -9.36M | -16.10M | -16.41M | -8.24M | -4.95M | -18.56M | -16.92M | -16.25M | 97.11M | - | -15.18M | -14.84M | -12.27M | -6.48M | -5.12M | -9.05M | -13.27M | -8.01M | -7.85M | - | -6.75M | -6.19M | -267.00K | 1.76M | 108.00K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11 | - | -0.38 | -0.36 | 2.11 | - | -0.33 | -0.32 | -0.27 | -0.14 | -0.11 | -0.20 | -0.28 | -0.17 | -0.17 | - | -0.14 | -0.13 | -0.01 | 0.04 | 0.00 |
| R&D Expense | - | 8.56M | 9.12M | 8.27M | - | 9.55M | 8.91M | 7.97M | - | 9.06M | 8.65M | 8.56M | - | 8.18M | 9.80M | 10.15M | - | 11.59M | 10.04M | 10.58M | - | 11.22M | 12.20M | 11.28M | - | 13.63M | 14.79M | 15.17M | 15.33M | 17.44M | 20.35M | 19.84M | 20.42M | 20.96M | - | 22.53M | 29.28M | 22.89M | - | 24.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 155.11M | 174.72M | 201.63M | 230.81M | 206.53M | - | 330.38M | 399.25M | 465.31M | 534.53M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.44M | 98.88M | 117.78M | 133.75M |
| Gross Profit | 41.78M | 45.39M | 47.00M | 50.01M | 59.56M | 75.75M | 92.88M | 111.10M | 126.16M | 147.12M | 170.34M | 149.31M | - | 245.94M | 300.37M | 347.52M | 400.78M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 288.61M | 327.05M | 387.54M | 410.23M |
| Operating Income | -15.51M | -3.19M | -4.73M | -7.20M | -10.89M | -16.36M | -26.72M | -31.14M | -24.98M | -17.13M | -33.12M | -44.23M | - | -42.67M | -26.68M | -40.01M | -9.45M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.50M | -8.11M | -18.53M | 16.25M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.99M | 6.92M | 6.41M | 5.88M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -46.20M | -29.85M | -43.67M | -10.16M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 268.00K | 591.00K | 1.02M | 1.28M |
| Net Income | -16.49M | -3.79M | -5.46M | -7.53M | -11.46M | -16.21M | -27.21M | -33.34M | -26.89M | -21.14M | -35.19M | -48.16M | 50.20M | -46.47M | -30.44M | -44.70M | - |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.94 | -1.14 | - | -1.02 | -0.66 | -0.95 | -0.24 |
| R&D Expense | 11.41M | 11.53M | 11.86M | 12.15M | 13.44M | 18.60M | 25.74M | 35.82M | 34.14M | 34.72M | 41.23M | 43.07M | 48.51M | 57.34M | 73.92M | 96.18M | 99.21M |
Compounded Sales Growth
| 5 Years: | 17.40% |
| 1 Year: | 14.30% |
Compounded Profit Growth
| 5 Years: | -63.01% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -19.96% |
| 6 Months: | -28.09% |
| 3 Months: | -11.48% |
| 1 Month: | +1.21% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 33.72M | 33.86M | 32.43M | 111.95M | 158.40M | 273.09M | 276.42M | 267.70M | 356.76M | 557.88M | 714.54M | - | 585.45M | 613.93M | - | 609.33M | 654.18M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 215.21M | 266.25M | - | 267.83M | 322.52M |
| Cash & Equivalents | 11.45M | 8.90M | 4.23M | 9.76M | 7.75M | 14.89M | 28.38M | 23.76M | 24.21M | 21.81M | 32.23M | 28.48M | 41.94M | - | 58.10M | 84.31M | - | 122.72M | 167.43M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.93M | 67.90M | - | 75.33M | 78.49M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.69M | 52.50M | - | 60.34M | 66.65M |
| Total Liabilities | - | - | 16.98M | 18.24M | 19.93M | 39.34M | 25.87M | 86.41M | 107.98M | 106.54M | 107.38M | 310.54M | 302.14M | - | 128.69M | 147.76M | - | 148.36M | 162.24M |
| Current Liabilities | - | - | 13.04M | 10.81M | 12.21M | 26.71M | 25.64M | 31.59M | 28.83M | 31.90M | 40.22M | 49.92M | 49.14M | - | 58.39M | 74.57M | - | 73.42M | 81.52M |
| Long Term Debt | - | - | - | - | - | - | - | - | 23.89M | 24.10M | 35.57M | 59.63M | 53.44M | - | 56.83M | 60.59M | 61.00M | 61.87M | 61.87M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.55M | 74.49M | - | 73.72M | 73.38M |
| Total Equity | 29.12M | 17.09M | 16.74M | 15.62M | 12.50M | 72.60M | 132.54M | 186.69M | 168.44M | 161.17M | 249.38M | 247.34M | 412.39M | - | 456.75M | 466.17M | - | 460.97M | 491.94M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.56M | 47.53M | - | 48.87M | 49.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 419.95K | -33.00K | -1.99M | -1.94M | -5.22M | - | -7.84M | -15.12M | -8.94M | -4.17M | -15.81M | -19.87M | - | -22.14M | 4.48M | 12.20M | 57.33M |
| Investing Cash Flow | -2.17M | -3.33M | 2.72M | -2.80M | -14.15M | - | -10.50M | -12.08M | 3.76M | -85.40M | -2.15M | -156.20M | - | 44.01M | 21.82M | 30.23M | -14.55M |
| Financing Cash Flow | -914.01K | -1.44M | 4.85M | 2.66M | 26.83M | - | 13.96M | 27.70M | 2.76M | 100.18M | 14.37M | 189.39M | - | -7.06M | -32.00K | -3.60M | 1.18M |
| Capital Expenditure | -1.36M | -1.81M | -1.52M | -2.98M | -2.86M | -5.51M | -13.45M | -7.69M | -6.38M | -6.21M | -12.18M | -5.26M | - | -16.88M | -42.00M | -23.46M | -15.05M |
| Free Cash Flow | -940.51K | -1.85M | -3.51M | -4.92M | -8.09M | - | -21.29M | -22.81M | -15.33M | -10.38M | -27.99M | -25.13M | - | -39.02M | -37.51M | -11.26M | 42.28M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.81M | 26.27M | 38.84M | 43.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 71.6% | 72.2% | 73.0% | 73.8% | 72.3% | - | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating Margin % | - | - | - | - | - | - | - | -20.1% | -14.3% | -8.5% | -14.4% | -21.4% | - | -12.9% | -6.7% | -8.6% | -1.8% |
| Net Margin % | - | - | - | - | - | - | - | -21.5% | -15.4% | -10.5% | -15.2% | -23.3% | - | -14.1% | -7.6% | -9.6% | - |
| ROE % | -96.5% | -22.7% | -34.9% | -60.3% | -15.8% | -12.2% | -14.6% | -19.8% | -16.7% | -8.5% | -14.2% | -11.7% | - | -10.2% | -6.5% | -9.7% | - |
| ROCE % | - | -15.4% | -20.5% | -35.6% | -12.8% | -12.3% | -11.1% | -12.6% | -10.6% | -5.4% | -6.5% | -6.6% | - | -8.1% | -4.9% | -7.5% | -1.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.98% | 4.04M | $111.86M |
| 2 | Wellington Management Group, LLP | 6.68% | 3.38M | $93.60M |
| 3 | Alliancebernstein L.P. | 6.44% | 3.26M | $90.17M |
| 4 | Hood River Capital Management LLC | 6.16% | 3.12M | $86.26M |
| 5 | Vanguard Portfolio Management LLC | 5.34% | 2.70M | $74.78M |
| 6 | Vanguard Capital Management LLC | 4.26% | 2.16M | $59.65M |
| 7 | Nomura Asset Management International Inc | 3.56% | 1.80M | $49.94M |
| 8 | Goldman Sachs Group Inc | 3.29% | 1.67M | $46.13M |
| 9 | Marshall Wace LLP | 2.90% | 1.47M | $40.61M |
| 10 | State Street Corporation | 2.57% | 1.30M | $36.03M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATRC